Tiragolumab Antibody
Tiragolumab (MTIG-7192A) is a TIGIT-targeting monoclonal antibody used in cancer immunotherapy research. It is frequently studied in combination with atezolizumab (anti-PD-L1) for solid tumors like NSCLC, with both in vitro assays and in vivo models demonstrating its role in blocking inhibitory checkpoints to enhance anti-tumor T-cell activity.
Product Specifications
Product Name Alternative
MTIG-7192A, RO7092284, RO-7092284, RO 7092284, RG6058, RG-6058, RG6058-10, RG6058-11, RG 6058, Tiragolumab
Target
Immunology/Inflammation related, Others
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation
Concentration
3.63 mg/mL
Purity
95.20% (May vary between batches)
Molecular Weight
148.3 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Tumor Necrosis Factor Receptor 2, p75/p80 (TNFR 2, TNFRII, CD120b, Etanercept, p75, p75TNFR, p80 TNF alpha Receptor, Soluble TNFR1B Variant 1, TNFR75, TNFR80, Tumor Necrosis Factor beta Receptor, TNFBR, Tumor Necrosis Factor Binding Protein 2, TBP2, TBPII, Tumor Necrosis Factor Receptor Superfamily Member 1B Precursor, TNFRSF1B, TNR1B)
